Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Funda Meric‐Bernstam, Junji Tsurutani et al.|Journal of Clinical Oncology|2024Cited by 158
Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric‐Bernstam, Senthil Damodaran|Clinical Cancer Research|2024Cited by 17
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A. Gouda, Funda Meric‐Bernstam, Amrit S. Gonugunta et al.|Clinical Cancer Research|2025Cited by 13
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T. Lei, Michael T. Lewis, Lacey E. Dobrolecki et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 3
Abstract 739: Patient-derived xenografts allow deconvolution and prediction of chemotherapy responsesJonathan T. Lei, Michael T. Lewis, Bryan E. Welm et al.|Cancer Research|2025Cited by 0